MG-K10 in Pediatric Atopic Dermatitis (6-12 Years)
A Phase Ib/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Pediatric Patients Aged 6 to 12 Years With Moderate to Severe Atopic Dermatitis
A Phase Ib/II Study of MG-K10 in Pediatric Patients (6-12 Years) with Moderate to Severe Atopic Dermatitis
Primary Objective:
To evaluate the safety of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe atopic dermatitis (AD).
Secondary Objectives:
To evaluate the pharmacokinetic (PK) characteristics, preliminary efficacy, pharmacodynamic (PD) characteristics, and immunogenicity of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe AD.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Ma
- 전화번호: 13601305676
- 이메일: bch_maleen2021@126.com
연구 장소
-
-
-
Shanghai, 중국
- Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china
-
연락하다:
- Chao Deng
- 전화번호: 15712950928
- 이메일: chao.deng@mabgeek.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Aged ≥6 years and <12 years (calculated based on the date of ICF signature), regardless of gender, with a baseline body weight ≥15 kg and <60 kg.
- Diagnosed with atopic dermatitis (AD) according to the American Academy of Dermatology (AAD) consensus criteria (2014), with a history of AD or eczema diagnosed for ≥6 months prior to screening (with disease onset defined as the date of first symptom appearance).
- Inadequate response to topical medications within 12 months prior to screening, or medically unsuitable for topical medication therapy.
- Participants and/or their parents or legal guardians voluntarily provide written informed consent. For participants aged ≥6 years and <8 years, signing an informed consent form is not required, but an assent form must be completed. Participants must be able to communicate effectively with the investigator and comply with protocol-required follow-up visits.
Exclusion Criteria:
- Unable to undergo subcutaneous injection
- Have other active skin diseases that may affect AD evaluation (such as psoriasis or lupus erythematosus);
- Have diseases that may require systemic glucocorticoid or immunosuppressant treatment;
- Patients with ocular diseases deemed unsuitable for enrollment by the investigator;
- Received allergen-specific immunotherapy within 6 months before dosing; Stopped all topical medications less than 2 weeks before dosing, including topical glucocorticoids, topical calcineurin inhibitors, antibiotic compound creams, topical TCM therapy;
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: A:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
|
실험적: B:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
|
실험적: C:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
|
실험적: D:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence and severity of adverse events
기간: Up to Week 24
|
Incidence and severity of AEs, plus abnormality rates/severity of vital signs, physical examination, clinical laboratory tests, and 12-lead ECG. |
Up to Week 24
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percent of Participants with Investigator's Global Assessment (IGA) 0/1 and ≥2-Point Improvement
기간: Each assessment visit through Week 16
|
Proportion achieving IGA score 0 or 1 AND ≥2-point reduction vs. baseline |
Each assessment visit through Week 16
|
|
Percent of Participants with ≥2-Point IGA Improvement
기간: Through Week 16
|
Proportion with IGA reduction ≥2 points vs. baseline |
Through Week 16
|
|
Percent of Participants Achieving EASI-50, EASI-75, or EASI-90
기간: Through Week 16
|
Proportion with ≥50%/75%/90% EASI reduction vs. baseline |
Through Week 16
|
|
Change in Lesion Body Surface Area (BSA)
기간: Through Week 16
|
Change in lesion body surface area |
Through Week 16
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- MG-K10-AD-007
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .